|30th September 2020||Charles B O'Keeffe||7,000||Open or private purchase||$2.99||$20,930.00|
|30th September 2020||Patrick J Mcenany||15,000||Open or private purchase||$2.97||$44,550.00|
|5th December 2019||Gary Ingenito||150,000||Open or private sale||$4.82||$723,150.00|
|4th December 2019||Gary Ingenito||150,000||Exercise of derivative||$2.53||$379,500.00|
|27th November 2019||Gary Ingenito||100,000||Exercise of derivative||$1.13||$113,000.00|
|27th November 2019||Gary Ingenito||100,000||Open or private sale||$4.66||$466,000.00|
|21st November 2019||Gary Ingenito||100,000||Open or private sale||$4.50||$449,800.00|
|20th November 2019||Gary Ingenito||100,000||Exercise of derivative||$0.79||$79,000.00|
|11th October 2019||Charles B O'Keeffe||10,000||Open or private purchase||$4.70||$46,950.00|
|3rd October 2019||Patrick J Mcenany||10,000||Open or private purchase||$4.89||$48,900.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Catalyst Pharmaceuticals is a biopharmaceutical company. The company was founded Huckel E. Hubert in January 2002 and is headquartered in Coral Gables, FL. It is developing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases.